Quontic Bank Appoints New Vice President of Specialty Banking

Quontic Bank has announced on Thursday that it has appointed Casey Christopher as the bank’s new Vice President of Specialty Banking with immediate effect. The new assigned responsibilities of the Casey to break the traditional banking system empower the innovative financial system to its existing and upcoming clients.

The newly appointed Bank’s Vice President of Specialty Banking has got years of extensive experience in the field of financial management and banking industry that would prove to be very beneficial for the upcoming ventures, partnership and deal of the bank.

In her new position, Casey will focus on delivering banking products, to improve financial outcomes and she will also help the Bank to become the career destination for women along with a new generation of financial and tech advisors.

Chief Executive Officer of Quontic Bank, Steve Schnail said, “We are ecstatic for Casey to be joining the Quontic team. We’ve been able to work together as partners for over a year now and have decided to join forces to continue pushing innovation in banking. Casey represents the type of proven leader Quontic seeks to attract and we are excited to watch her create value for our customers, partners, employees, and Quontic itself.

“Casey embodies the heart of what we are striving to do at Quontic. We look forward to onboarding Casey as a leader in banking, and welcome her as our new Vice President of Specialty Banking,”Schnail further added.

Sharing her thoughts over the appointments, Casey said, “Breaking the system means disassembling our thoughts, beliefs and actions on why and how we do things and putting it all back together to improve our customers’ experience.”

“I have been fortunate enough to have great mentors in the industry that have inspired me to envision new programs that are pathways to change. Alongside the team at Quontic, these ideas will become reality. Working at a CDFI allows me to marry my respect for community banks and my desire to make positive changes in our community- striking a balance between profits and purpose. I couldn’t be more excited about my career at Quontic and all the great things we will do together,” Casey continued.

Premier Medical Laboratory Services Reports Radical Increase In Covid-19 Testing With OnGem LIMS Cloud System

Premier Medical Laboratory Services has announced that it has witnessed the phenomenal increase in the testing of Covid-19 pandemic due to the implementation of OnGen Laboratory Information Management System (LIMS). The healthcare company has further added that now with the integration of OnGen LIMS Cloud System, the company can easily perform up to 620,000 COvid-19 pandemic tests per month.

Premier Medical Laboratory Services has added that it has achieved this milestone after streamlining and integrating its existing laboratory processes with the platform of OnGen LIMS Cloud System. One of the best features of the OnGen Cloud System is that it seamlessly integrates with any existing Electronic Medical Record System (EMR) that a number of physicians and hospitals are currently using. With the help of the company’s cloud system, the medical laboratories can significantly expand their workflow by increasing the virus testing ratio, which would never be possible without integrating the OnGen LIMS cloud system.

Chief Information Officer and President at OnGen, Ryan Piper said, “Our team developed the OnGen platform with scalability to enhance any laboratory’s testing volume while maintaining FDA and CDC regulations.”

“The cloud-based technology that the platform employs is an advanced innovative solution to the laboratory infrastructure shortage that our country is facing with COVID-19 testing. We are proud to see how our platform is helping laboratories to successfully manage the unprecedented influx of testing demands in preparation for America to reopen,” Ryan Piper further added.

Founder of Premier Medical Laboratory, Kevin Murdock said, “OnGen is the technology solution that we found most effective in streamlining our workflow and automating many of our lab processes that would otherwise be done manually. This has allowed us to increase our testing capacity from 124,000 to 620,000 tests per month and we are now able to better serve the increasing amount of physicians who count on us to provide results for their patients.”

Radiko Holding Completes Its Transaction With BioNeva

Radiko Holdings, a leading cannabis-focused company, has announced on Monday May 11, 2020 that the company has successfully completed its transaction with Nevada-based BioNMeva Innovations of Carson City.

According to the details released by the company, BioNeva is a leading cannabis cultivator that holds cannabis cultivation licenses of both recreational and medical marijuana. The company has got the fully operational facility of one acre of leased land from outside and 8,250 f ft2 for indoor cannabis cultivation. The facility is equipped with the highly efficient auxiliary lighting systems, roof glazing material can canopy of 4,000 ft2.

Chief Executive Officer of the Radiko Holdings, Steve Gormley said, “This transaction adds significant enterprise value, and furthers our corporate development strategy of acquiring select, highly-profitable value chain investments to facilitate brand growth, enhance margins and bolster cash flow. We appreciate the patience of our shareholders as we worked to finalize this transaction amid COVID-19, and we look forward to reporting our progress as we execute our plan.”

Holder and Director of BioNeva Innovations of Carson City, Bob Yosaitis said, “I am extremely pleased that Radiko and BioNeva are able to join forces and create broader opportunities for both organizations. The Radiko team has extensive cannabis experience and the expertise to build successful operations for both the Carson City [BioNeva] and Washoe locations, and the addition of cultivation should contribute significantly to overall earnings and provide a valuable platform for Radiko’s portfolio of brands.”

About Radiko Holdings:

Radiko Holdings is a cannabis-focused company that offers the best commercial products to compliment the consumer’s lifestyles. The company’s mission is to market and build a wide range of cannabis-based products to support EBITDA. The company markets its products with permitted THC content for medical and recreational use.

Nuvo Pharmaceuticals Announced Q1 2020 Financial Results

Nuvo Pharmaceuticals, a Canada-based leading healthcare company featuring a wide range of commercial products, has announced the Q1 2020 financial results of the company on Monday May 11, 2020. According to the details released by the company, the total revenue of the company increased up to 11% and stood at 18.9 million USD, as compared to 17.1 million USD for the previous three months.

The company’s two commercial products Cambia and Blexton have collected total revenue up to 6.0 million USD, which has increased 94$ as compared to the past three months.

The company has further said that it had made the principal loan payment of 11.5 million USD in the three months ended March 31, 2020.

The adjusted EBTIDA of the company stood at 8.0 million USD, which increased up to 52% as compared to the past three months ended March 31, 2020.

Chief Executive Officer and President of Nuvo Pharmaceuticals, Jesse Ledger said, “The COVID-19 pandemic has been the overriding focus of the world over the last couple of months. During this time, Nuvo continues to operate as an essential business. We have made necessary changes so we can continue to operate and supply our healthcare products to global partners, wholesalers, pharmacies, and ultimately patients, while ensuring our employees remain safe and healthy.”

“Despite the challenges presented by the COVID-19 pandemic, we are making progress in achieving a number of anticipated milestones in the second quarter, including the launch of Resultz in Germany and the submission of the Blexten pediatric dossier to Health Canada, and we continue to prepare for the Canadian commercial launches of Suvexx and Neovisc Plus and Neovisc One later this year. Furthermore, Blexten and Cambia continued their strong performance in the first quarter,” Jesse Ledger further added.

Ellis Island Honors Society Speeds Up Covid-19 Relief Activities

Ellis Island Honors Society or EIHS, a leading US-based organization with a mission to foster tolerances and preserve cultural diversity among ethnic groups, has announced on Friday May 1, 2020 that the company is speeding up the Covid-19 relief efforts by fundraising campaign for healthcare provider and medical centers, which are worst affected by the pandemic.

According to the PR Newswire News Agency, the fundraising campaign was started by the Combat Go and Black Belt Magazine. These two companies help to launch the virtual martial arts magazine, Fight Back, featuring World’s leading Martial Artists.

Ellis Island Honors Society (EIHS) is registered as the non-profit organization and it will help to raise the funds, as 100% amount of the donated amount would be going to the American Red Cross to speed up Covid-19 relief activities.

Chairman of Ellis Island Honors Society (EIHS), Nasser Kazeminy said, “My heart and prayers go out to all who are suffering through this crisis or providing care for loved ones who are afflicted.”

“And my greatest respect to those volunteering in service to others. This is the time to stand together, under one flag, and do what we can to help America and our fellow citizens,” Nasser Kazeminy further said.

Co-Founder and Chief Executive Officer of Jungo TV and Former Martial Arts Champion, George Chung said, “During these uncertain times, it gives us hope to see how people all over the world are finding new and innovative ways to stay connected.”

“We are honored to be part of this global martial arts experience Fight Back with our partners Black Belt Magazine, Bellator, and Ellis Island Honors Society to support the American Red Cross in the global fight to end COVID-19,” CEO of Jungo TV George Chung further added.

Stroke Surgeons Kicks Off National Stroke Awareness Month With Plea For Vigilance Amid The Covid-19 Pandemic

As the connection of stroke and Covid-19 pandemic is growing, its even more necessary to immediately inform the emergency number to treat the stroke rather than waiting to turn the stroke into a pandemic. This guidance is given by the Stroke Surgeons during kicking of the National Stroke Awareness Month. Furthermore, the Stroke Surgeons plead to ensure maximum social distancing during the ongoing Covid-19 pandemic.

It is a fact that stroke can lead to the long-term disability and even the patient in the normal conditions. Each year, more than 800,000 US people suffer from the stroke and about 140,000 people losé their lives due to it along with many more left disabled for the rest of their lives. Prominent Stroke Surgeons have said that there is a high probability that the US might get record a number of stroke-related death due to the ongoing Covid-19 pandemic.

Prominent Stroke Surgeon of Mount Sinai Hospital in Newyork, Dr. J Mocco said, “The connection between COVID-19 and stroke is real. After an initial drop in stroke cases in the time leading up to surge, the number of stroke patients doubled during the COVID-19 peak and more than half were COVID-19 positive. What’s more, these patients were on average 15 years younger than typical stroke patients and among the least likely to otherwise have a stroke.”

A prominent Stroke Surgeon with UW Medicine in Seattle, Dr. Michael Levitt said, “Patients should know that stroke units in hospitals are taking every precaution to protect our patients and our staff from COVID-19 exposure.”

“What remains unchanged throughout this pandemic is that we still need to play it safe when it comes to stroke and always call 9-1-1. Avoiding or delaying treatment will only lead to more deaths,” Dr. Michael Levitt further added.

Eye Catching Stock News: PTC Therapeutics (NASDAQ:PTCT)

PTC Therapeutics (NASDAQ:PTCT)  stock identified change of 61.66% away from 52-week low price and recently located move of -16.88% off 52-week high price. It has market worth of $3.03BM. PTCT stock has been recorded 2.27% away from 50 day moving average and 9.68% away from 200 day moving average. Moving closer, we can see that shares have been trading 14.34% off 20-day moving average.

On April 17, 2020, PTC Therapeutics (NASDAQ:PTCT) notified the appointments of Matthew Klein, M.D., to Chief Development Officer and Eric Pauwels to Chief Business Officer. Dr. Klein will be responsible for the development of our clinical stage programs. As the Chief Business Officer, Mr. Pauwels will be responsible for our customer facing activities with health care providers, patients and payers ensuring that our therapies are available and accessible to rare disease patients and their families worldwide.

I am very pleased to announce these well-deserved appointments to PTC’s Executive Committee, said Stuart Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics Matt and Eric are both recognized industry leaders with demonstrated track records of success. In their new roles, they will continue to advance our development pipeline, fuel our company’s growth and deliver on our mission to develop and provide transformative therapies for patients living with rare disorders.

Dr. Klein joined PTC last year as Global Head of Gene & Mitochondrial Therapies after serving as Chief Executive Officer and Chief Medical Officer of BioElectron Technology Corporation, certain assets of which were acquired by PTC in 2019. Prior to leading BioElectron, Dr. Klein was the Auth-Washington Research Chair of Restorative Burn Surgery at the University of Washington. Dr. Klein holds a Bachelor of Arts in History, and graduated summa cum laude and phi beta kappa from the University of Pennsylvania in Philadelphia, Pennsylvania and a Doctor of Medicine from Yale University School of Medicine in New Haven, Connecticut.

The Healthcare sector company, PTC Therapeutics noticed change of 4.82% to $49.78 along volume of 953191 shares in recent session compared to an average volume of 973.03K. The stock observed return of 9.58% in 5 days trading activity. The stock was at 34.47% over one month performance. PTCT’s shares are at -5.13% for the quarter and driving a 40.54% return over the course of the past year and is now at 3.64% since this point in 2018.

The average volatility for the week at 4.85% and for month was at 8.22%. There are 60.87M shares outstanding and 60.65M shares are floated in market. Right now the stock beta is 1.54.

Cognizant Technology Solutions Corporation (NASDAQ:CTSH) announces updates in response to the impact of the novel coronavirus (COVID-19)

Cognizant Technology Solutions Corporation (NASDAQ:CTSH) is now trading -27.41% off 52-week high price. On the other end, the stock has been noted 35.67% away from the low price over the last 52-weeks. The stock changed 5.62% to recent value of $54.28. The stock transacted 6155119 shares during most recent day however it has an average volume of 4.66M shares. The company has 559.89M of outstanding shares and 547.33M shares were floated in the market.

On April 9, 2020, Cognizant Technology Solutions Corporation (NASDAQ:CTSH) one of the world’s leading professional services companies, reported certain updates in response to the impact of the novel coronavirus (COVID-19) on business operations.

Our priorities remain the health and safety of our associates and the business continuity of our clients, said Brian Humphries, Chief Executive Officer. We are committed to helping our clients as they navigate unprecedented business challenges as well as supporting the efforts of governments globally to contain the spread of the virus.

I am pleased with our business momentum in the first two months of the quarter and grateful for the dedication and professionalism of our associates in March, both of which enabled us to meet our previously announced revenue guidance. We acted decisively to limit COVID-19’s impact on our business, including rapidly enabling work-from-home capabilities across our delivery teams. We will continue to take steps to protect our associates and support the evolving needs of clients in ‘s environment.

In this fluid environment where uncertainty prevails, we are well-positioned with deep client relationships across more than a dozen industries, and a strong balance sheet that provides solid financial flexibility. As ever, we stand committed to help our clients manage through economic, technological and other disruptions through our innovative solutions and talented associates, Humphries continued. I am proud of our 292,000 associates who have risen to the challenge of serving our clients with empathy, initiative and courage, and confident that we will emerge from this global crisis stronger together.

Its earnings per share (EPS) expected to touch remained -8.40% for this year while earning per share for the next 5-years is expected to reach at 7.96%. CTSH has a gross margin of 36.60% and an operating margin of 14.60% while its profit margin remained 11.00% for the last 12 months.

According to the most recent quarter its current ratio was 2.6 that represents company’s ability to meet its current financial obligations. The price moved ahead of 15.83% from the mean of 20 days, -5.17% from mean of 50 days SMA and performed -11.20% from mean of 200 days price. Company’s performance for the week was 22.56%, 2.15% for month and YTD performance remained -12.48%.

Notable News to Watch: Centene Corporation (NYSE:CNC)

Centene Corporation (NYSE:CNC)spotted trading -12.41% off 52-week high price. On the other end, the stock has been noted 44.43% away from the low price over the last 52-weeks. The stock changed 10.11% to recent value of $60.12. The stock transacted 4361869 shares during most recent day however it has an average volume of 6.60M shares. The company has 605.73M of outstanding shares and 575.77M shares were floated in the market.

On April 6, 2020, Centene Corporation (NYSE:CNC) released that it is establishing a Medical Reserve Leave policy to support clinical staff who want to join a medical reserve force and serve their communities, during the COVID-19 pandemic. The policy will support clinical staff by providing paid leave and benefits for up to three months of volunteer service.

Our employees have a deep commitment to take care of their communities in times of need and we will always support their passion to serve, said Michael Neidorff, Chairman, President and CEO of Centene. Our medical reserve leave policy will ensure our clinical staff are paid and that their benefits are protected during their time of service.

If an employee decides to take advantage of the medical reserve leave benefit, they will:

  • Maintain pay in accordance with the number of hours regularly scheduled to work;
  • Maintain enrolled benefit coverage as an active employee;
  • Continue to accrue paid time off; and
  • Maintain eligibility for holiday pay for any holidays that occur during the time of service.

Its earnings per share (EPS) expected to touch remained 39.10% for this year while earning per share for the next 5-years is expected to reach at 13.63%. CNC has a gross margin of 17.80% and an operating margin of 2.30% while its profit margin remained 1.80% for the last 12 months.

According to the most recent quarter its current ratio was 1.6 that represents company’s ability to meet its current financial obligations. The price moved ahead of 8.75% from the mean of 20 days, 1.36% from mean of 50 days SMA and performed 10.36% from mean of 200 days price. Company’s performance for the week was 4.18%, 2.66% for month and YTD performance remained -4.37%.

BMO Financial Group (NYSE:BMO) completed the acquisition of Clearpool Group

BMO Financial Group (NYSE:BMO) stock observed trading -37.46% off 52-week high price. On the other end, the stock has been noted 30.49% away from low price over the last 52-weeks. The stock disclosed a move of -21.16% away from 50 day moving average and -30.35% away from 200 day moving average. Moving closer, we can see that shares have been trading 6.43% off 20-day moving average. It has market cap of $32.46B and dividend yield of 6.38%.

On April 6, 2020, BMO Financial Group (NYSE:BMO) reported that it has completed the acquisition of Clearpool Group, a New York-based provider of holistic electronic trading solutions and an independent agency broker-dealer operating in the U.S. and Canada.

BMO announced the acquisition on January 22, 2020. The transaction delivers powerful new capabilities to BMO’s electronic trading platform. As the nature of equity trading shifts to increased emphasis on electronic trading, the acquisition of Clearpool demonstrates BMO’s commitment to delivering leading edge trading technology to its global client base.

Clearpool continues to be a separate broker-dealer with information barriers to secure clients’ confidential information.

The acquisition is not expected to have a significant impact on the financial results of the bank and will reduce CET1 ratio by approximately 10bps.

In connection with the transaction, BMO Capital Markets acted as financial advisor and Debevoise & Plimpton LLP and Osler, Hoskin & Harcourt LLP acted as legal counsel to BMO.  Financial Technology Partners acted as financial advisor and Morgan, Lewis, & Bockius LLP, Murphy & McGonigle and Stikeman Elliott LLP acted as legal counsel to Clearpool.

The Canada based company Bank of Montreal moved with change of 5.53% to $49.99 with the total traded volume of 822354 shares in recent session versus to an average volume of 925.55K. The stock was observed in the 5 days activity at 4.43%. The one month performance of stock was -20.58%. BMO’s shares are at -35.51% for the quarter and driving a -34.58% return over the course of the past year and is now at -35.50% since this point in 2018.  Right now the stock beta is 1.25. The average volatility for the week and month was at 4.69% and 8.10% respectively. There are 649.39M shares outstanding and 639.22M shares are floated in market.